It’s been over a year since COVID-19 emerged and DrugBank has been at the forefront of COVID antiviral research. Our two co-founders, Mike Wilson and Craig Knox, sit down (virtually) with Arden Tse from the Accelerate Fund.

In a groundbreaking announcement, a Food and Drug Administration (FDA) advisory panel gave their unanimous recommendation in April 2018 for the approval of Epidiolex, a cannabis-derived product shown to be effective for the treatment of two forms of treatment-resistant childhood epilepsies.

Progress on resistance: The discovery of malacidins, a class of chemicals made by bacteria found in soil, is an exciting advancement and will hopefully make way for near future discovery of much needed broad-spectrum antibiotics.

Orkambi and Kalydeco are members of a new generation of medications that are making history for people living with Cystic Fibrosis. These treatments focus on improving underlying lung function rather than simply delaying its decline...